




























































Inflammation and reduced endothelial function in the
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89Systemic inflammation andelevated circulating levels of the endogenous nitric oxide
inhibitor asymmetrical dimethylarginine (ADMA) have been associated with in-
creased risk in cardiogenic shock (CS). In this prospective study, we assessed, over
4 consecutive days, the changes and possible associations between vascular func-
tion, markers of inflammation, and circulating ADMA levels in patients with CS
(n 5 12) and postcardiotomy heart failure (n 5 12, PC-HF). Vasodilator function was
measured as a reactive hyperemia index (RH-index) using a finger plethysmograph.
Blood samples were analyzed for plasma ADMA, interleukine-6, interleukine-8, intra-
cellular adhesion molecule-1, and vascular adhesionmolecule-1. Baseline RH-index
was significantly attenuated compared with healthy controls (2.28) for both CS and
PC-HF (1.35 and 1.45, respectively, P5 .001). Although vasodilator function improved
in PC-HF patients, it remainedattenuated inCS. Inflammatorymarkers weremarkedly
elevated followed by a significant fall during the observation period in both groups.
ADMA levels increased significantly during the observation period for PC-HF, whereas
nopatternof changewasobserved forCS.Noassociationwas foundbetween the lon-
gitudinal changes in RH-index, markers of inflammation, or ADMA in CS. However, an
improved RH-index was associated with decreasing inflammatory markers in PC-HF.
ADMA correlated to arterial lactate levels and the degree of organ dysfunction in
CS. In conclusion, CS and PC-HF were characterized by a marked inflammatory
activation accompanied by an attenuated vasodilator function. ADMA was related
to organ dysfunction and degree of hypoperfusion during CS but showed no correla-
tions to inflammation or hampered vasodilator function. The pathogenic significance






96Abbreviations: ADMA ¼ asymmetrical dimethylarginine; CABG ¼ coronary artery bypass graft-
ing; CCU¼ coronary care unit; CPR ¼ cardiopulmonary resuscitation; CS ¼ cardiogenic shock;
DDAH¼ dimethylarginine dimethylaminohydrolase; HR¼ heart rate; IABP¼ intra-aortic balloon
pump; iCAM-1¼ intracellular adhesionmolecule-1; ICU¼ intensive care unit; IL-6¼ interleukine
6; IL-8 ¼ interleukine 8; IQR ¼ interquartile range; IS ¼ inotropic score; MAP ¼ mean arterial
pressure; NO ¼ nitric oxide; PC-HF ¼ postcardiotomy heart failure; RH-index ¼ reactive hyper-
emia index; SOFA ¼ Sequential Organ Failure Assessment; TNFa ¼ tumor necrosis factor a;
vCAM-1 ¼ vascular cell adhesion molecule-1thoracic and Vascular Surgery,
ay; and Department of Clinical
l Biology, The Health Faculty,
rway.
30, 2010; revision submitted
blication December 10, 2010.
Reprint requests: Stig Eggen Hermansen, Department of Cardiotho-
racic and Vascular Surgery, University Hospital of North Norway,
9038 Tromsø, Norway; e-mail: stig.eggen.hermansen@unn.no.
1931-5244/$ - see front matter
 2011 Mosby, Inc. All rights reserved.
doi:10.1016/j.trsl.2010.12.002
1











AT A GLANCE COMMENTARY
Hermansen S, et al.
Background
Systemic inflammation and elevated levels of the
endogenous NO-inhibitor asymmetrical dimethy-
larginine (ADMA) are associated with poor out-
comes in acute severe heart failure. How these
risk markers relate to each other and their signifi-
cance in the pathophysiology and vascular dys-
function in the course of cardiogenic shock (CS)
is, however, unknown.
Translational Significance
We observed a marked inflammatory response and
attenuated vasodilator function in the acute phase
of CS. ADMA correlated to the degree of hypoper-
fusion and organ dysfunction. A substantial degree
of individual and time-related fluctuations in these
parameters demonstrates the challenges in clarify-
ing the pathophysiological mechanisms in the cir-
culatory dysfunction during CS.
Translational Research












































































































214Recent clinical trials and registries on patients with car-
diogenic shock (CS) have demonstrated the heterogene-
ity of this severely ill patient population with regard to
etiology as well as clinical and hemodynamical presen-
tation.1-4 The current understanding of the underlying
pathophysiology that marks patients with an unfavor-
able course and lack of response to treatment is limited.
This was evident in the recently published Triumph trial
that addressed the possible adverse effects of a presumed
excessive nitric oxide (NO) production secondary to
inflammation in CS.5 In this study, treatment with an
unselective NO inhibitor in patients with persisting
shock failed to reduce the duration of shock and
mortality. However, observational studies have sug-
gested that systemic inflammation and neurohormonal
activation plays an important role in the pathogenesis
of CS.3,6-10
The naturally occurring NO-inhibitor asymmetrical
dimethylarginine (ADMA) has been implicated in the
pathogenesis of endothelial dysfunction and several
chronic cardiovascular disorders.11-14 In contrast to its
increasing recognition as a risk marker in cardiovascu-
lar disease, little is known about ADMA’s role in the
acute setting. Experimental studies, however, have dem-
onstrated adverse hemodynamic effects after systemic
administration of ADMA in humans.15 Furthermore,
ADMA has been indicated to be an independent predic-
tor for a poor outcome in critical illness and CS.16,17FLA 5.1.0 DTD  TRSL400_proof  11Elevated levels of ADMA also have been observed in
patients with acute decompensated heart failure as com-
pared with chronic heart failure.18 However, a recent
study on acute heart failure failed to confirm these find-
ings, and ADMA also did not seem to identify patients
with increased risk for future cardiac events including
episodes of decompensation.19 However, at this time,
the biological significance and possible regulatory role
of ADMA as a modulator of NO production and thus
as a vascular function in acute heart failure is not
known.
It is necessary to characterize and establish the differ-
ent factors modulating the circulation in patients with
severe pump failure. Ultimately, these observations
hopefully will identify and tailor an optimal medical
treatment for different subgroups of patients.
The main aim of this observational study therefore
was to examine the changes and possible relations
among the endogenous NO inhibitor ADMA, vascular
vasodilator function and markers of inflammation, and
endothelial activation during the course of severe acute
heart failure (ie, CS and postcardiotomy heart failure).
In addition, we assessed their association with organ
dysfunction and patient outcomes.METHODS
Study population. The study population consisted of
24 prospectively included patients admitted to the inten-
sive care unit (ICU) or coronary care unit (CCU) at the
University Hospital of North Norway between 2007 and
2009 with either CS or postcardiotomy heart failure
(PC-HF). Our institution is a university hospital serving
a population of approximately 500,000. Informed writ-
ten consent was obtained from each patient if possible
or the nearest relative. The study protocol was approved
by the regional ethics committee (REK-Nord 51/2004)
and conforms with the ethical guidelines outlined in
the Declaration of Helsinki.
CS was defined as cardiac dysfunction with persistent
hypotension (systolic blood pressure,90mmHg) or the
need for vasopressor/inotropic drug support to keep sys-
tolic blood pressure greater than 90 mmHg in combina-
tion with signs and symptoms of tissue hypoperfusion
despite a correction of preload. Signs of systemic hypo-
perfusion included altered mental state, cool skin and
extremities, low urine output (,0.5 mL/kg/h), or ele-
vated arterial lactate. PC-HF was defined as inadequate
cardiac performance after open-heart surgery in need of
inotropes/vasopressors and/or mechanical circulatory
support for more than 2 h after surgery with or without
signs of systemic hypoperfusion. The PC-HF group did
not include patients where an intra-aortic balloon pump
(IABP) was implanted preoperatively to improveJanuary 2011  2:17 pm  ce
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322a critical coronary perfusion in otherwise circulatory
stable patients, and this support was continued postoper-
ativelywithout the need for additional inotropic support.
Exclusion criteria were age,18 years and recent major
surgery other than heart surgery. Data on prior medical
history were obtained from the patients medical charts
at study entry. Basic hemodynamic variables including
mean arterial pressure (MAP), heart rate (HR), central
venous pressure, and blood gas analyses (arterial pH,
base excess) were recorded at study inclusion in all
patients and thereafter daily at the time of the vascular
functional assessments. Invasive hemodynamic moni-
toring with pulmonary artery catheter was not obliga-
tory in the study protocol and only applied on clinical
indication. To give an estimate of the severity of circu-
latory compromise, the concomitant requirements of
inotropic and/or vasopressor agents were presented as
total vasopressor dose (epinephrine 1 norepinephrine)
and inotropic score (IS). IS summarizes the total dosing
equivalents of inotropes and vasopressors in mg/kg/min
(dopamine1 dobutamine1milrinone3 151 epineph-
rine 3 100 1 norepinephrine 3 100).20,21 The occur-
rence of organ dysfunction and failure, from
admission through day 4, was assessed by the Sequential
Organ Failure Assessment (SOFA) score.22 The maxi-
mal SOFA scorewas calculated based on theworst score
for each organ component in this time period. The
neurological subscore was not included because of the
high number of patients under sedation both at onset
of heart failure and during ICU/CCU treatment. A
SOFA subscore $3 was defined as organ failure.
Blood sampling and biochemical assays. Blood sam-
ples were collected in ethylenediaminetetraacetic acid
containing tubes at baseline (day 1) and for the next
3 consecutive days. Plasma samples were frozen imme-
diately after centrifugation and stored at 270C until
subsequent analysis. To determine plasma ADMA con-
centration, samples were assayed using a commercially
available competitive enzyme immunoassay kit
(ADMA-ELISA, DLD Diagnostika GMBH, Hamburg,
Germany). As a normal control, ADMA levels were de-
termined in plasma from 12 healthy volunteers (mean
age 5 35 years). Markers of endothelial activation,
(intracellular adhesion molecule-1 [iCAM-1] and
vascular cell adhesion molecule-1 [vCAM-1]) and
the inflammatory markers interleukine 6 (IL-6),
interleukine 8 (IL-8) all were quantified in duplicates
using a bead-based multiplex assay (Bioplex; Bio-Rad
Laboratories, Hercules, Calif). Final plasma
concentrations were calculated using the Bioplex
software supplied by the manufacturer.
Measurement of peripheral vasodilator
function. Peripheral vasodilator function was assessed
with noninvasive digital pulse amplitude tonometryFLA 5.1.0 DTD  TRSL400_proof  11using the EndoPAT 2000 (Itamar Medical Ltd, Cae-
sarea, Israel). This device provides user-independent
measurements of the vasodilator function during
reactive hyperemia with a fingertip plethysmograph
measuring pulsatile blood volume changes in digital
microvessels reflecting the peripheral arterial tone.
This method is shown to correlate with flow mediated
dilatation of the brachial artery.23,24 Measurements
were performed bedside at study inclusion and for the
next 3 consecutive days with patients in a supine
position. Reactive hyperemia was induced by a 5-min
occlusion of the upper arm at approximately
60 mmHg higher than systolic blood pressure. Both
sides were measured simultaneously to allow for
adjustments of systemic changes in arterial tone by
correcting for changes in the nonoccluded arm.
Results were analyzed using automated analysis
software (EndoPAT 2000 software version 3.1.2) that
calculates a ratio between baseline and hyperemic
pulsatile volume changes presented as a reactive
hyperemia index (RH-index). The RH-index was
measured in 10 healthy volunteers with a mean RH-
index 2.28 (SD 6 0.42). Previous studies on healthy
subjects have reported mean RH-index values around
1.9 to 2.0.23,25,26
Statistics. Continuous variables are presented as me-
dian with interquartile range (IQR). c2 statistics were
used to compare categorical variables. Student t test
was used to compare variables with normal distribution,
whereas Mann-Whitney U test was used for
nonnormally distributed variables. Changes in RH-
index and plasma levels of ADMA, IL-6, IL-8, iCAM,
and vCAM through the observation period were
analyzed using a linear mixed model. All variables
needed transformation before the statistical analysis. A
linear mixed model also was used to examine for
associations among changes in RH-index, ADMA
levels with the concomitant day-to-day changes in
MAP, and laboratory variables as covariates.
Correlations between baseline variables were assessed
with Spearman’s ranked correlation coefficient (rs) or
Pearson’s correlation coefficient (r). A 2-tailed P value
,0.05 was considered statistically significant. The
SPSS 16.0 software was used for all statistical analysis
(Chicago, Ill).RESULTS
Study population. Patient characteristics including
prior medical history, precipitating factors for acute
heart failure, and in hospital procedures are presented in
Table I. Most patients with CS presented with acute
myocardial infarction and were treated with early
percutaneous coronary interventions. Two patients inJanuary 2011  2:17 pm  ce
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429this group had coronary bypass surgery during
hospitalization. Treatment with intra-aortic balloon
pumps and inotropes/vasopressors were applied in most
patients. The open-heart surgical procedures prior to
PC-HF included 4 isolated coronary artery bypass
grafting (CABG) procedures, 4 aortic valve
replacements (2 redo procedures), 1 mitral valve
replacement and CABG, 1 composite graft replacement
in the ascending aorta and CABG, 1 procedure on the
thoracic aorta, and 1 redo closure of left ventricular
rupture. No significant differences were found between
the 2 groups with regard to the need for inotropic/
vasopressor support. However, the duration of IABP
support tended to be longer for CS patients (P5 0.057).
Baseline hemodynamic variables and laboratory
variables are presented in Table II. Mean time from
the onset of acute heart failure to the initial blood
sampling and endothelial function measurement was,
respectively, 17 and 19 h. CS patients showed on aver-
age more severe derangements in their blood gas at
baseline suggesting a more profound hypoperfusion in
this group. This coincided with significantly lower
diuresis and systolic blood pressure.
Markers of inflammation and endothelial
activation. Circulating levels of IL-6, IL-8, iCAM-1,
and vCAM-1 were not different at baseline between the
2 groups (Table II). IL-6 levels decreased from baseline
through day 4 for both CS (P 5 0.013) and PC-HF
(P , 0.001) and was significantly lower on days 3 and 4
compared with baseline (Fig 3, A). Similar longitudinal
changes were observed for IL-8 levels with a significant
decrease for both CS (P 5 0.004) and PC-HF
(P , 0.001) (Fig 3, B). IL-6 was negatively correlated
with MAP in both CS (rs 5 –.57, P , 0.001) and
PC-HF (rs 5 –.567, P , 0.001). Increased IL-6 levels at
baseline also were associated with increased need for
vasopressors in CS patients (rs 5 .65, P5 0.02).
Circulating levels of iCAM and vCAM did not
change from days 1 to 4 for any of the groups (Fig 3,
C and D). iCAM and vCAM were correlated in both
groups (CS rs 5 .66, P , 0.0001, PC-HF rs 5 .73,
P , 0.0001).
Digital vasodilator function. Satisfactory measurements
were obtained in 86 out of 94 potential recordings. Poor
patient cooperation and failure to receive a readable dig-
ital pulse signal were the main reasons for missing data.
The measured RH-index at baseline (day 1) was
significantly attenuated compared with healthy controls
(RH-index, 2.28) for both CS (RH-index 1.35, P 5
0.001) and PC-HF (RH-index 1.45, P 5 0.001). The
baseline RH-index was not significantly different
between CS and PC-HF (Table II). Also, no significant
changes were noted in RH-index for days 1 through 4FLA 5.1.0 DTD  TRSL400_proof  11for CS patients (Fig 1, A, P 5 0.521). In patients with
PC-HF, the RH-index changed significantly through the
observation period (P 5 0.019) and was increased at
days 3 and 4 compared with baseline (Fig 1, A, P 5
0.011). The individual repeated measurements for both
groups are displayed in Figures 1, B and C and illustrate
the variability among patients both at baseline and
during the course of their illness. At baseline, RH-index
positively correlated with MAP in PC-HF patients (rs 5
.70, P 5 0.017). This association also was present
when all recordings were pooled (rs 5 .55, P ,
0.0001). RH-index also correlated to ADMA levels at
baseline (rs 5 2.633, P 5 0.036) for CS patients but
not for PC-HF patients. No correlation was found
among the measured RH-index and systolic blood
pressure, IS, or vasopressor requirements at baseline.
A linear mixed effect model was used to examine for
associations among day-to-day changes in RH-index;
the concomitant changes in MAP; and plasma levels
of ADMA, IL-6, IL-8, iCAM-1, vCAM-1. In patients
with PC-HF, increasing MAP and decreasing levels of
IL-6 and IL-8 was associated with improvement in
RH-index. The only significant correlate for improved
RH-index in CS patients was decreasing levels of
vCAM-1. We could not detect a significant association
between the longitudinal changes in RH-index and
ADMA levels in either of the groups.
ADMA. The measured plasma levels of ADMA are
shown in Figure 2. Baseline levels of ADMA in CS
were similar to those measured in healthy volunteers
(0.74 vs 0.79 mmol/L, P 5 0.67) but significantly
elevated compared with PC-HF (0.55 mmol/L, P 5
0.04). A group difference also was found in the course
of ADMA levels from baseline through day 4 (Fig 2).
ADMA levels increased in patients with PC-HF (P 5
0.001) and was significantly elevated compared with
baseline at day 3 (P 5 0.017) and at day 4 (P 5
0.001). No significant longitudinal changes were
observed for CS patients (P 5 0.58). Repeating
the analysis excluding patients receiving hemodialysis
or hemofiltration (2 patients in CS group) did not
change these relations. However, a significant positive
association was found between the longitudinal
changes in ADMA and creatinine (P 5 0.032) through
the observation period. Patients who underwent
cardiopulmonary resuscitation prior to CS onset had
significantly higher baseline ADMA levels (1.05 vs
0.58 mmol/L, P 5 0.003). In CS patients, baseline
ADMA levels correlated with both lactate measured at
baseline (rs 5 .85, P 5 0.001) and the maximal
lactate measured within 48 h (rs 5 .90, P , 0.001).
This association was not present in PC-HF patients.
No correlations were found between baseline ADMAJanuary 2011  2:17 pm  ce
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Table I. Study population. Baseline characteristics, precipitating factors, and in hospital treatment and
outcomes
CS (n 5 12) PC-HF* (n 5 12)
Age, years (mean,range) 65.8 (49–85) 70.7 (58–79)
Male gender, n 8 10
Prior medical history, n
Coronary heart disease 5 7
Myocardial infarction 5 4
Chronic heart failure 3 3
Hypertension 8 2*
Severe valvular disease 0 6
Diabetes 3 4
Stroke/TIA 3 0
Renal failure 1 0
Chronic obstructive pulmonary disease 3 0
Current smoking 4 3
Precipitating factors, n








Other heart surgery, n 0
Mechanical ventilation, n 7 8†
Pulmonary artery catheter, n 6 3
Ventricular assist device, n 2 1
IABP, n 11 10
Duration of IABP support, h 167 (65–240) 55 (39–180)
Inotropes, n 11 11
Vasopressors, n 10 12
Duration of vasopressor/inotropic support, h 84 (55–148) 51 (24–94)
Maximal vasopressor dose‡,§ 0.10 (0.01–0.28) 0.13 (0.07–0.21)
Maximal IS‡ 18.5 (5.2–31.0) 17.2 (12.4–30.0)
Hemofiltration or hemodialysis, n 2 0
Length of ICU/CCU stay, days 10 (5–17) 7 (3–14)
Maximal SOFA score** 7.5 (6.0–14.8) 8.5 (5.3–11.5)
Organ failure,†† n 5 6
In hospital mortality, n 5 2
ContinuousEQ1 variables are presented as median with IQR if not stated otherwise.
PCI, percutaneous coronary intervention; TIA, transitory ischemic attack.
*Surgical procedures are presented under methods.
†Patients necessitating intubation exceeding the first postoperative day.
‡Measured within the first 48 h.
§Given as the total dose of epinephrine and norepinephrine (ug/kg/min).
{Cardiopulmonary resuscitation prior to inclusion.
**Total seguential organ failure assessment score (SOFA) score except neurological SOFA subscore.
††Failure of $1 organ other than cardiovascular failure.
‡‡P , 0.05 compared with CS.
Translational Research












































































































538and the need for vasopressors or IS. Baseline ADMA
levels did correlate with baseline MAP for PC-HF
patients (rs 5 .73, P 5 0.007) but not for CS patients.
No association between day-to-day changes in ADMA
and changes in MAP, IL-6, IL-8, iCAM-1, vCAM-1
could be observed in either group.
In hospital outcome and organ dysfunction. Hospital
mortality rates in CS and PC-HF was, respectively, 42%FLA 5.1.0 DTD  TRSL400_proof  11and 17 %. However, only 1 fatality occurred during the
first 4 days of follow-up (CS group). No significant
difference was found in RH-index and baseline levels of
ADMA, IL-6, IL-8, iCAM-1, and vCAM-1 between
hospital survivors and nonsurvivors. The maximal total
SOFA score (excluding neurological subscore) for days
1 through 4 was not significantly different between CS
and PC-HF patients (Table I).January 2011  2:17 pm  ce
Table II. Baseline laboratory and hemodynamic variables
CS n 5 12 PC-HF n 5 12
CK-mb (mg/L), maximal value 207 (47–493) 56 (25–133)
Plasma creatinine (mmol/L) 125 (99–183) 85 (81–121)
eGFR (mL/min) 57 (40–114) 84 (63–102)
Lactate (mmol/L), Baseline* 3.3 (1.8–7.9) 1.9 (1.5–6.2)
Highest value† 3.3 (1.8–8.4) 5.2 (2.1–7.0)
Arterial pH, Baseline* 7.26 (7.11–7.31) 7.36 (7.29–7.43)§
Lowest value† 7.20 (7.05–7.30) 7.26 (7.13–7.34)
Base excess(mmol/L), Baseline* 27.7 (212.6– 23.9) 24.4 (25.7– 21.8)§
Lowest value† 28.1 (217.8– 23.9) 26.2 (212.5– 22.7)
C-reactive protein (mg/L) 33 (9–135) 69 (10–121)
White blood cells (109/L) 17.2 (9.8–19.8) 9.5 (5.4–11.7)§
ADMA (umol/L) 0.62 (0.52–1.11) 0.51 (0.37–0.68)§
IL-6 (pg/mL) 281 (131–459) 342 (197–691)
IL-8 (pg/mL) 121 (26–122) 57 (43–140)
iCAM-1 (ng/mL) 96 (64–152) 98 (88–269)
vCAM-1 (ng/mL) 349 (257–441) 367 (311–412)
RH-index 1.35 (1.27–1.56) 1.45 (1.00–1.86)
Mean arterial blood pressure (mmHG) 60 (56–67) 64 (57–68)
Systolic blood pressure (mmHG) 80 (75–85) 90 (80–99)§
Diastolic blood pressure (mmHG) 53 (46–58) 50 (40–55)
Cardiac index (L/min/m2)‡ 2.18 (1.51–2.47)
SVRI (dynes*sec/cm5*m2)‡ 2097 (1961–2576)
Diuresis, ml/hour 10 (0–29) 68 (25–91)§
HR (beats per min) 110 (85–120) 88 (85–99)
Values are presented as median with IQR.
CK-mb, creatine kinase mb; eGFR, estimated glomerular filtration rate; SVRI, systemic vascular resistance index.
*First measurement after onset of CS or PC-HF.
†Measured within first 48 h.
‡n 5 6. eGFR calculated using the modification of diet in renal disease formula.
§P , 0.05 compared with cardiogenic shock.
Translational Research












































































































646In CS patients, the SOFA score was correlated to
baseline RH-index (rs 5 2.69, P 5 0.014), baseline
ADMA levels (rs 5 .630, P 5 0.028), baseline IL-6
(rs5 .62, P5 0.03), and IL-8 (rs5.78, P5 0.007). Fur-
thermore, baseline ADMA levels were strongly corre-
lated to the hepatic (rs 5 .79, P 5 0.003) and
respiratory (rs 5.77, P 5 0.004) SOFA subscores,
whereas no significant associations were observed for
the other organs including the kidneys (rs 5 .55, P 5
0.065). ADMA levels increased in 7 patients and de-
creased in 5 patients through the observation period.
A negative correlation existed between the absolute
change in ADMA levels and the degree of hepatic and
respiratory dysfunction (rs 5 2.63, P 5 0.024 and
rs 5 2.71, P 5 0.01, respectively). CS patients with
failure of an organ other than the central nervous system
or cardiovascular system had lower baseline RH-index
(median 1.22 vs 1.51, P5 0.01), elevated ADMA levels
(median 0.58 vs 1.05 umol/L, P5 0.005), and increased
IL-8 (median 27 vs.150 pg/mL) compared with patients
without organ failure. A tendency alsowas noted toward
increased IL-6 levels in CS patients with organ failure,
but this finding was not statistically significant (132 vs
343 pg/mL, P 5 0.202).FLA 5.1.0 DTD  TRSL400_proof  11For patients with PC-HF, no association was found
among SOFA scores and baseline RH-index, ADMA,
or IL-6. IL-8 did, however, correlate to SOFA score
(rs 5 .79, P 5 0.002). Accordingly, baseline RH-
index, ADMA, IL-8, and IL-6 were not different in pa-
tients with organ failure compared with those without.
Also, no correlation was found between the change in
ADMA levels and any of the SOFA subscores. No asso-
ciation was evident among iCAM-1, vCAM-1, and
SOFA scores in any group.DISCUSSION
Our study shows that patients with the most severe
forms of acute heart failure (ie, CS and PC-HF) are sub-
ject to a profound inflammatory insult evident by exces-
sive circulating levels of IL-6 and IL-8, markedly higher
than reported in acute decompensated heart failure and
acute myocardial infarction.9,10,27 These levels are com-
parable with the levels measured in sepsis.7,28,29 This
finding was accompanied by a sustained elevation in
markers of endothelial activation. Although the sys-
temic inflammatory insult and endothelial activation in-
flicted by open-heart surgery and use of extra corporealJanuary 2011  2:17 pm  ce
Fig 2. The course of plasma ADMA levels measured at days 1–4. A,Mean plasma ADMAwith SEM. Individual
changes in plasma ADMA levels for CS (A) and PC-HF patients (B). One patient in the cardiogenic shock group
died at day 2. *P , 0.05 compared with day 1. #P , 0.05 compared with PC-HF at day 1.
Fig 1. RH-index measured at days 1–4.A,Mean RH-index with SEM. Individual values of the repeated RH-index
measurements for CS patients B, and PC-HF patients C. One patient in the CS group died at day 2. *P , 0.05
compared with day 1. # P , 0.05 compared with CS and PC-HF at day 1.
Translational Research












































































































754bypass is well described,30 the cause and consequence
of this in CS is less well understood. However, the pre-
viously described association between IL-6 levels and
vasopressor requirements to restore blood pressure in
CS also was evident in our study as high IL-6 levels
were both related to low MAP and increased vasopres-
sor dose.6
The peripheral vasodilator function was assessed seri-
ally through the first 4 days after acute heart failure on-
set. The RH-index was impaired at baseline in both
groups compared with healthy controls. This finding
was, however, not uniform as several individuals had
a preserved RH-index indicating a preserved vascular
and endothelial function. A few prior studies have as-
sessed vascular reactivity in shock and critical illness
demonstrating impaired vascular response during reac-
tive hyperemia. Kirschenbaum et al found an attenuated
increase in forearm blood flow after reactive hyperemia
in patients with cardiogenic and septic shock compared
with healthy controls.31 A similar observation was made
in patients with severe sepsis using peripheral arterial
tonometry similar to the present study.29 The repeatedFLA 5.1.0 DTD  TRSL400_proof  11assessments in our study also revealed a substantial in-
dividual day-to-day variation. This finding underlines
that vascular function and probably endothelial function
in acute disease are not static, which is an important
consideration to make when assessing vascular function
in acute versus chronic disease states.
The mechanisms behind the apparent attenuation in
vasodilator function and the changes observed through
the course of the disease are likely to be multifactorial
and probably a composite of prior vascular/endothelial
function and a multitude of superimposed acute factors.
The peripheral vasculature in CS and PC-HF is subject
to an immense and changing stimulus from circulating
hormones, the sympathetic nervous system, and local
metabolic factors capable of modulating both endothe-
lial and vascular function.32-34 Also, fewer functional
capillaries secondary to intravascular obstruction or oe-
dema could blunt the reactive hyperemic response in
critical disease.35 The RH-index, as a measure of the pe-
ripheral circulations ability to respond to transitory lo-
cal ischemia, is likely a result from all these factors.
Being in part NO-dependent, the impaired RH-indexJanuary 2011  2:17 pm  ce
Fig 3. A, Circulating plasma levels of IL-6. B, IL-8. C, iCAM-1. D,
vCAM-1. One patient in the CS group died at day 2. *P , 0.05 com-
pared with day 1 for CS patients. #P , 0.05 compared with day 1 for
PC-HF patients.
FLA 5.1.0 DTD  TRSL400_proof  11
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861at baseline could suggest a reduced endothelial NO bio-
availability.25 The negative relation observed between
the endogenous NO-inhibitor ADMA and the RH-
index at baseline in CS could suggest an inhibitory ef-
fect of ADMA on vasodilator function. However, no
longitudinal association was found between the two to
back up this hypothesis. Also, this relation was not
observed in PC-HF. It is possible that attenuation of
other important contributors to endothelium dependent
dilation, such as prostacyclin or endothelium derived
hyperpolarizing factor, play a bigger role. Interestingly,
the observed improvement in vasodilator function in
PC-HF was associated with a concomitant decrease in
inflammatory cytokines. A transitory impairment of
endothelial function after exposure to cytokines and
transitory inflammation has been described in an exper-
imental setting and possibly could explain the effects
observed here.36,37 Furthermore, tumor necrosis factor
a(TNFa) and IL-6 also have been shown to induce
endothelium-dependent vasoconstriction in human
arterial segments.38
Role of ADMA in CS and PC-HF. Circulating ADMA
levels were similar in CS and healthy controls. The nor-
mal values found in this study coincide well with a re-
cently proposed normal reference value (mean 0.69,
95% confidence interval: 0.36–1.17 mmol/L) and other
reports using a similar enzyme-linked immunosorbent
assay technique.39,40 This is in contrast to previous
reports measuring elevated levels of ADMA after
acute decompensated heart failure and CS using high-
performance liquid chromatography and mass
spectrometry, respectively.16,18 A significant elevation
was, however, evident in the most critically ill CS
patients in our cohort with high arterial lactate and
organ failure.
Baseline ADMA levels were suppressed in PC-HF,
and although no pattern of change was apparent during
the first 4 days in CS, ADMA tended to increase in PC-
HF patients. This could possibly be caused by a hemodi-
luting effect of extra corporeal circulation, as initially
suppressed postoperative ADMA levels previously
have been demonstrated in patients undergoing open-
heart surgery.41,42 This consideration is important to
make when using ADMA as a risk marker in critically
ill patients in whom surgery has been done. The rela-
tively suppressed ADMA levels in PC-HF also could re-
flect that, in our population of patients, this condition is
more benign and that most of these patients were in
a state of recovery as compared with CS. However, no
indication was given that the degree or course of inflam-
mation and endothelial activation were related to
ADMA levels. Except for the observed correlation
with MAP at baseline in PC-HF, ADMA levels wereJanuary 2011  2:17 pm  ce
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970not related to blood pressure or vasopressor/inotrope
requirements.
Elevated ADMA levels were associated with the over-
all degree of organ dysfunction (SOFA score) and ele-
vated systemic lactate in CS. Accordingly, CS patients
with organ failure had significantly higher ADMA levels.
In particular, this elevationwas related to the degree of re-
spiratory and hepatic dysfunction. Although baseline
ADMA levels were not significantly correlated with the
renal SOFA score, the longitudinal positive association
betweenADMAand creatininewere consistentwith prior
reports that ADMA accumulates secondary to renal dys-
function.43 These observations are in line with findings
presented in previous reports from patients with severe
sepsis and in critically ill patients with organ fail-
ure.17,44,45 Accumulation of ADMA is thought to occur
mainly through reduced metabolism secondary to dysre-
gulation and inhibition of the dimethylarginine dimethy-
laminohydrolase (DDAH).46 This enzyme is highly
expressed in both liver and kidneys, which are presumed
to be themain routs formetabolic clearance of circulating
ADMA. However, ADMA levels were highest in patients
receiving cardiopulmonary resuscitation (CPR) either be-
fore or at the onset of shock. It is likely that these patients
had the most profound systemic hypoperfusion. Unlike
septic patients, the observed early elevated lactate levels
in CS patients are likely a result of systemic hypoperfu-
sion rather than liver failure. It is from the available
data not possible to determine whether patients in shock
already have accumulated levels of ADMA or if they de-
velop this after shock onset secondary to acute reduction
in hepatic or renal elimination. IncreasedADMAlevels in
patients who had CPR and/or had elevated arterial lactate
could indicate that ADMA as a marker of elevated risk in
CS merely reflects the severity of hypoperfusion during
shock. However, ADMA also could potentially play
a causative role in hypoperfusion and development of or-
gan failure through inhibiting the NO-mediated regula-
tion of organ blood flow.47
Although ADMAwas increased in patients with fail-
ing organs compared with those without, these patients
did not accumulate more ADMA during the observation
period. On the contrary, ADMA decreased more in pa-
tients with the highest degree of hepatic dysfunction.
Our study did not support an association between the
degree of systemic inflammation and circulating
ADMA. In vitro studies on endothelial cells, however,
have demonstrated that oxidative stress, stimulation
with TNFa, and nitrosative stress resulting from an in-
duction of inducible NO synthase cause an accumula-
tion of ADMA secondary to reduced DDAH
activity.48,49 However, increased DDAH activity sec-
ondary to stimulation with inflammatory cytokine
have been reported in rat vascular smooth muscleFLA 5.1.0 DTD  TRSL400_proof  11cells,50 and a mechanistic knowledge of the important
metabolic responses and the regulation of the NO-
system and vasculature is still warranted.
LIMITATIONS
The vascular function measurements were performed
in a clinical setting in the ICU/CCU on patients receiv-
ing several different pharmacological and mechanical
treatments through the observation period. This lack
of standardization could affect the quality of these mea-
surements. Invasive hemodynamics were only mea-
sured in 1/4 of the patients, and thus, no evaluation of
RH-index in relation to changing hemodynamics could
be performed. Also, multiple statistical comparisons
based on a limited number of patients inherits the risk
of type I errors.
CONCLUSION
In this study, both CS and PC-HF were characterized
by initially elevated levels of inflammatory cytokines
suggestive of a profound inflammatory insult accompa-
nied by an attenuated peripheral vasodilator function.
The resolving inflammatory response was associated
with improved RH-index in PC-HF patients, whereas
no such relation was evident for CS patients. The circu-
lating levels of the endogenousNO-inhibitor ADMAdid
not relate to the degree of inflammation or to the day-to-
day changes in vasodilator function. However, in CS,
ADMA, vasodilator function, and levels of inflamma-
tory cytokines were correlated to the overall degree of
organ dysfunction, and to hepatic dysfunction in partic-
ular. The increased ADMA levels in patients who had
CPR and/or elevated arterial lactate suggest a relation
between ADMA and the degree of hypoperfusion in CS.
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